Home > News > MIV Therapeutics Inc.'s HAp Nano Stent Coating
March 8th, 2005
MIV Therapeutics Inc.'s HAp Nano Stent Coating
Abstract:
MIV Therapeutics Inc., a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, announced today the successful completion of pilot preclinical studies of hydroxyapatite (HAp) coated stents in pig coronary arteries.
Source:
businesswire
Bookmark:
| Related News Press |
Nanomedicine
How cells repair DNA’s protective barrier: a pathway to address a rare genetic disorder characterized by rapid aging in children December 13th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
FSU researchers develop new methods to generate and improve magnetism of 2D materials December 13th, 2024
Innovative biomimetic superhydrophobic coating combines repair and buffering properties for superior anti-erosion December 13th, 2024
Groundbreaking research unveils unified theory for optical singularities in photonic microstructures December 13th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||